Each year, more people die of lung cancer than colon, breast and prostate cancers combined. Learn how Johnson & Johnson is dedicated to improving outcomes by integrating the company’s MedTech and Innovative Medicine expertise.

The goal of precision medicine is to develop individualized treatments based on a patient’s genetic profile. Here’s how Johnson & Johnson is harnessing this cutting-edge field of tailor-made medicine.

Learn about one patient’s journey toward getting an accurate diagnosis—and why it’s crucial to always advocate for your health.

As both a cancer survivor and caregiver, Shauna Smith knows the power of feeling supported when facing the disease. That’s why she founded Johnson & Johnson’s Cancer Focus Group—so every employee has somewhere to turn if they or someone they love is faced with a diagnosis.

When Craig was diagnosed with multiple myeloma, his wife Cara took on a new role: caregiver. Here, she shares the challenges—as well as the triumphs—of this difficult journey.

Rates of this blood cancer have jumped more than 125% worldwide since the 1990s. But there’s reason to have hope: Today, life expectancy has at least doubled in some cases. That’s thanks to increased research, new learnings and innovative advances—and Johnson & Johnson is at the forefront of this crucial work.

The Johnson & Johnson WiSTEM2D Scholars Award Program winners have big ideas—and an even bigger drive to inspire other women studying science, technology, engineering, math, manufacturing and design to pursue their dreams, too.

For National Cancer Prevention Month, we’re spotlighting three leading Johnson & Johnson female hematologists—innovators who are not only saving lives and advancing new treatments but also paving the way for the next generation of women in their field.

Algorithms, artificial intelligence, machine learning and other technologies are transforming the way physicians identify, treat and manage diseases. Here’s how Johnson & Johnson is putting the latest tools to work.

That’s exactly what researchers at Johnson & Johnson are trying to find out. By partnering on a new study that’s looking at the role gut microbes may play in the disease—and focusing on the underrepresented groups most affected—they hope to advance early-detection strategies and potential treatments.